Open AccessThe Potential of some Plant Extracts as Radical Scavengers and Dipeptidyl Peptidase-4 Inhibitors
Author(s) -
Malik Et al.
Publication year - 2019
Publication title -
mağallaẗ baġdād li-l-ʿulūm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.167
H-Index - 6
eISSN - 2411-7986
pISSN - 2078-8665
DOI - 10.21123/bsj.2019.16.1(suppl.).0162
Subject(s) - gallic acid , chemistry , dpph , acetone , methanol , polyphenol , botany , butanol , olea , food science , distilled water , traditional medicine , horticulture , ethanol , antioxidant , biochemistry , organic chemistry , chromatography , biology , medicine
Seeds, beans, leaves, fruit peel and seeds of five plants (Ferula assa-foetida, Coffea robusta, Olea europaea, Punica granatum and Vitis vinifera, respectively) were extracted with four solvents (distilled water, 80% methanol, 80% acetone and a mixed solvent that included methanol, ethanol, acetone and n-butanol at proportions 7:1:1:1). Such manipulation yielded 20 extracts, which were phytochemically analyzed for total polyphenols (TP) and flavonoids (TF). The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity (RSA) and DPP-4 (dipeptidyl peptidase-4) relative inhibition activity (RIA) were also assessed for each extract. The results revealed that mixed solvent extract of V. vinifera seeds showed the highest content of TP (194.8 ± 2.5 mg Gallic acid equivalent/g dry mass), while methanol extract of V. vinifera seeds recorded the highest content of TF (75.9 ± 0.3 mg catechin equivalent/g dry mass). The C. robusta bean aqueous extract was remarkable in scoring the highest DPPH RSA (87.2 ± 1.2%), while O. europaea leaf methanol extract had the highest DPP-4 RIA (86.4 ± 0.8%). In conclusion, the importance of natural products as radical scavengers and DPP-4 inhibitors is encouraged, and such biological effects were dependent on the plant species and the solvent of extraction. C. robusta beans are suggested to have a prominent RSA, while O. europaea leaves are recommended to be a target for investigations involved in the development of anti-T2DM therapies.